Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis

LA JOLLA, Calif.–(BUSINESS WIRE)—- $EQ–Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Biocon Limited, in collaboration with Equillium, has initiated a Phase 2 clinical study of itolizumab in patients with ulcerative colitis (UC). The Phase 2 double-blinded placebo-controlled clinical study is evaluating the safety and efficacy of itolizumab for biologics-naïve p
Click here to view original post